Consolidated Financial Results
for the Fiscal Year Ended March 31, 2026 (IFRS)

May 8, 2026

Company name	: **ONO PHARMACEUTICAL CO., LTD.**
Stock exchange listing	: Tokyo Stock Exchange
Securities Code	: 4528
URL	: https://www.ono-pharma.com/en
Representative	: Toichi Takino President
Inquiries	: Ryuta Imura Vice President of Corporate Communications
Telephone	: +81-(0)6-6263-5670
Scheduled date of annual general meeting of shareholders	: June 18, 2026
Scheduled date of securities report submission	: June 15, 2026
Scheduled date of dividend payment commencement	: June 19, 2026
Supplementary materials for the financial results	: Yes
Earnings announcement for the financial results	: Yes (for institutional investors and securities analysts)

(Note: Amounts of less than one million yen are rounded.)

1. Consolidated Financial Results for FY 2025 (April 1, 2025 to March 31, 2026)

(1) Consolidated Operating Results (cumulative)

IFRS (Full) basis (% change from the previous fiscal year)

	Revenue		Operating profit		Profit before tax		Profit for the year		Profit attributable to owners of the Company		Total comprehensive income for the year	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%
FY 2025	515,785	5.9	92,236	54.4	92,654	56.2	69,911	39.4	69,767	39.4	103,695	258.7
FY 2024	486,871	(3.1)	59,747	(62.6)	59,328	(63.8)	50,166	(60.8)	50,047	(60.9)	28,905	(79.0)

	Basic earnings per share	Diluted earnings per share	Return on equity attributable to owners of the Company	Ratio of profit before tax to total assets	Ratio of operating profit to revenue
	Yen	Yen	%	%	%
FY 2025	148.49	148.41	8.5	8.5	17.9
FY 2024	106.55	106.41	6.4	6.0	12.3

Core basis

	Revenue		Core operating profit		Core Profit for the year		Basic core earnings per share
	Million yen	%	Million yen	%	Million yen	%	yen
FY 2025	515,785	5.9	137,135	21.7	103,499	14.5	220.28
FY 2024	486,871	(3.1)	112,667	(37.7)	90,361	(36.6)	192.38

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of the Company	Ratio of equity attributable to owners of the Company to total assets	Equity attributable to owners of the Company per share
	Million yen	Million yen	Million yen	%	Yen
As of March 31, 2026	1,106,515	856,643	850,727	76.9	1,810.44
As of March 31, 2025	1,064,046	788,203	782,451	73.5	1,665.61

(3) Consolidated Cash Flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at the end of the fiscal year
	Million yen	Million yen	Million yen	Million yen
FY 2025	136,821	(39,860)	(65,493)	237,046
FY 2024	82,459	(136,785)	94,299	204,567

2. Dividends

	Annual dividends per share					Total dividends (annual)	Dividend payout ratio (consolidated)	Ratio of dividends to equity attributable to owners of the Company (consolidated)
	End of first quarter	End of second quarter	End of third quarter	End of fiscal year	Total			
	Yen	Yen	Yen	Yen	Yen	Million yen	%	%
FY 2024	—	40.00	—	40.00	80.00	37,582	75.1	4.8
FY 2025	—	40.00	—	40.00	80.00	37,929	53.9	4.6
FY 2026 (Forecast)	—	40.00	—	40.00	80.00		52.9	

3. Consolidated Financial Forecast for FY 2026 (April 1, 2026 to March 31, 2027)

IFRS (Full) basis (% change from the previous fiscal year)

	Revenue		Operating profit		Profit before tax		Profit for the year		Profit attributable to owners of the Company		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
FY 2025	455,000	(11.8)	94,000	1.9	94,000	1.5	71,000	1.6	71,000	1.8	151.09

Core basis (% change from the previous fiscal year)

	Revenue		Core operating profit		Core profit for the year		Basic core earnings per share
	Million yen	%	Million yen	%	Million yen	%	Yen
FY 2025	455,000	(11.8)	124.000	(9.6)	93,000	(10.1)	197.91

(Note) Revisions to financial forecast most recently announced: None

Notes

(1) Significant changes in scope of consolidation during the period: Yes
Newly included : 1 company (Company name) Ono Global Reinsurance, Inc

(2) Changes in accounting policies and changes in accounting estimates
1) Changes in accounting policies required by IFRS: None
2) Changes in accounting policies due to other than (2) – 1) above: None
3) Changes in accounting estimates: None

(3) Number of shares issued and outstanding (common stock)
1) Number of shares issued and outstanding as of the end of the period (including treasury shares):
As of March 31, 2026 498,692,800 shares
As of March 31, 2025 498,692,800 shares
2) Number of treasury shares as of the end of the period:
As of March 31, 2026 28,785,489 shares
As of March 31, 2025 28,919,831 shares
3) Average number of shares outstanding during the period:
FY 2025 469,852,850 shares
FY 2024 469,693,257 shares

Note: The Company has introduced a share grant ESOP trust, and the treasury shares held by this trust are included in treasury shares to be deducted when calculating the number of treasury shares outstanding at the end of the period and the weighted-average number of shares outstanding during the period.

* Review of the attached consolidated financial statements by certified public accountants or an audit firm: None

* Note to ensure appropriate use of forecasts, and other comments in particular
Forecasts and other forward-looking statements included in this report are based on information currently available and certain assumptions that the Company deems reasonable. Actual performance and other results may differ significantly due to various factors. Please refer to "(4) Future Outlook" on page 8 for information regarding the consolidated financial forecasts.

Index of the Attachment

1. Overview of Operating Results and Other Information 2
(1) Overview of Operating Results for the Fiscal Year 2025 2
(2) Overview of Financial Position for the Fiscal Year 2025 7
(3) Overview of Cash Flows for the Fiscal Year 2025 7
(4) Future Outlook 8
(5) Basic policy for profit distribution and dividends for the fiscal year under review and the following fiscal year 9

2. Basic Approach to the Selection of Accounting Standards 9

3. Consolidated Financial Statements and Major Notes 10
(1) Consolidated Statement of Financial Position 10
(2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income 12
(3) Consolidated Statement of Changes in Equity 14
(4) Consolidated Statement of Cash Flows 15
(5) Notes to Consolidated Financial Statements 16
(Note Regarding Assumption of Going Concern) 16
(Material Accounting Policies) 16
(Segment Information) 16
(Earning per Share) 17
(Significant Subsequent Event) 17

1. Overview of Operating Results and Other Information

(1) Overview of Operating Results for the Fiscal Year 2025

① Overview of Financial Results (Core basis)

(Millions of yen)

	Fiscal year ended March 31, 2025	**Fiscal year ended March 31, 2026**	Change	Change (%)
Revenue	486,871	**515,785**	28,914	5.9%
Core operating profit	112,667	**137,135**	24,468	21.7%
Core profit for the year (attributable to owners of the Company)	90,361	**103,499**	13,139	14.5%

[Revenue]

Revenue totaled ¥515.8 billion, which was an increase of ¥28.9 billion (5.9%) from the previous fiscal year (year on year).

<Sales of Domestic Products>

- Sales of domestic products totaled ¥281.4 billion, which was a decrease of ¥10.3 billion (3.5%) year on year.
- Sales of Opdivo Intravenous Infusion for malignant tumors decreased by ¥6.0 billion (5.0%) year on year to ¥114.3 billion, mainly due to the intensified competitive environment. Sales of Forxiga Tablets for diabetes, chronic heart failure and chronic kidney disease decreased by ¥1.4 billion (1.5%) year on year to ¥88.2 billion, mainly due to the entry of generic products in December 2025.
- With respect to other main products, sales of Orencia Subcutaneous Injection for rheumatoid arthritis were ¥26.6 billion (0.0% decrease year on year). Sales of Glactiv Tablets for type-2 diabetes were ¥13.2 billion (27.9% decrease year on year). Sales of Velexbru Tablets for malignant tumors were ¥11.9 billion (12.8% increase year on year). Sales of Ongentys Tablets for Parkinson's disease were ¥9.0 billion (17.3% increase year on year). Sales of Parsabiv Intravenous Injection for Dialysis for secondary hyperparathyroidism on hemodialysis were ¥9.0 billion (6.6% increase year on year). Sales of Kyprolis for Intravenous Infusion for multiple myeloma were ¥7.5 billion (12.9% decrease year on year). Sales of Braftovi Capsules for malignant tumors were ¥5.6 billion (33.8% increase year on year).

<Sales of Overseas Products>

- Sales of overseas products totaled ¥61.2 billion, which was an increase of ¥22.1 billion (56.5%) year on year.
- Sales of QINLOCK® (ripretinib) for gastrointestinal stromal tumor, marketed by Deciphera Pharmaceuticals, LLC, the operating company of Deciphera Pharmaceuticals, Inc., increased by ¥12.9 billion (50.6%) year on year (the previous period included only nine months of sales from July to March) to ¥38.4 billion. Additionally, sales of ROMVIMZA® (vimseltinib), also marketed by Deciphera, for tenosynovial giant cell tumor (TGCT) treatment, were ¥8.3 billion.

<Royalty and Others>

- Royalty and others increased by ¥17.1 billion (10.9%) year on year to ¥173.2 billion, mainly due to an increase in royalty revenue from Bristol-Myers Squibb Company.

[Core Operating Profit]

Core operating profit was ¥137.1 billion, an increase of ¥24.5 billion (21.7%) year on year.

- Cost of sales was ¥107.0 billion, roughly unchanged from the corresponding period of the previous fiscal year.
- Research and development costs increased by ¥1.8 billion (1.2%) year on year to ¥145.1 billion mainly due to the inclusion of research and development expenses from Deciphera Pharmaceuticals, LLC (the previous period accounted for only nine months of Deciphera's expenses (July to March), whereas the current period includes twelve months (April to March)), despite a decrease in research costs.
- Selling, general, and administrative expenses (except for research and development costs) increased by ¥1.4 billion (1.1%) year on year to ¥123.6 billion mainly due to the inclusion of business operating costs from Deciphera Pharmaceuticals, LLC (the previous period accounted for only nine months of Deciphera's expenses (July to March), whereas the current period includes twelve months (April to March)), despite ongoing efforts to improve cost efficiency.

[Core profit for the year] (attributable to owners of the Company)

Core profit attributable to owners of the Company increased by ¥13.1 billion (14.5%) year on year to ¥103.5 billion.

② Overview of Financial Results (IFRS (Full) basis)

The consolidated results for the current fiscal year on a full basis are shown in the table below.
Operating profit, profit before tax, and profit for the year attributable to owners of the parent all increased compared with the previous fiscal year.

Performance on a full basis includes items that are excluded from a core basis, such as amortization of intangible assets, impairment losses, and cost of inventories measured at fair value.

In the current fiscal year, amortization of intangible assets amounted to ¥25.6 billion (previous fiscal year: ¥14.6 billion), and impairment losses were ¥2.1 billion (previous fiscal year: ¥8.0 billion), and cost of inventories measured at fair value amounted to ¥9.1 billion (previous fiscal year: ¥12.9 billion).

Cost of sales in the previous fiscal year included a sales milestone payment of ¥13.6 billion related to Forxiga Tablets, which were sold under the co-promotion agreement with AstraZeneca.

Other expenses in the current fiscal year include the following major items:

- A loss of ¥4.3 billion representing the difference between the consideration received for the transfer of selling rights following the termination of the co-promotion agreement with AstraZeneca and the decrease in the carrying amount of the selling rights for Forxiga Tablets.
- A loss of ¥1.7 billion associated with revisions to the retirement benefit plan following the transition to a defined contribution pension plan
- A loss of ¥1.4 billion associated with product recall related to certain products

(Millions of yen)

	Fiscal year ended March 31, 2025	**Fiscal year ended March 31, 2026**	Change	Change (%)
Revenue	486,871	**515,785**	28,914	5.9%
Operating profit	59,747	**92,236**	32,489	54.4%
Profit before tax	59,328	**92,654**	33,326	56.2%
Profit for the year (attributable to owners of the Company)	50,047	**69,767**	19,720	39.4%

For details of the core adjustments, please refer to page 3 of the supplementary materials.

③ Research & Development Activities

Upholding the corporate philosophy “Dedicated to the Fight against Disease and Pain”, our group takes on the challenge against diseases that have not been overcome so far, and the disease area which has a low level of patient satisfaction with treatment and high medical needs. We are endeavoring to make creative and innovative new drugs.

In drug discovery research, we focus on the areas of oncology, immunology and inflammation, neurology; all of which include diseases with high medical needs. We aim to delve into human disease biology within each of these domains to develop new drugs that can meet these medical needs. By actively promoting open innovation, which is one of our strengths, we identify unique drug discovery seeds and enhance our drug discovery capabilities by utilizing optimal modalities and advanced technologies such as digital technology.

In our priority therapeutic areas, we currently have 28 new drug candidates in clinical development, 19 of which were made in-house. We are also continuing to bolster our efforts in translational research, bridging the gap between basic and clinical research to accelerate drug discovery timelines and boost success rates. By organically leveraging informatics and research tools, such as human genome data and human iPS cells in the early stages of research, we are working to analyze the relationship between target molecules and diseases to identify physiological indicators (biomarkers) that can more accurately predict and evaluate the efficacy of new drug candidates in humans.

Our current development pipeline comprises both in-house compounds and multiple in-licensed products, with development focused on diseases with high unmet medical needs, including oncology, autoimmune diseases, and neurological disorders. In particular, we are intensifying efforts to establish POC (proof of concept: the confirmation of safety and efficacy of a newly conceived drug candidate, originally developed at the research stage, through administration to humans) at an early stage to expand our late-stage development pipeline. To this end, our research and development functions work closely together from early phases to formulate optimal development strategies and clinical trial designs. We also utilize data and clinical samples obtained from past in-house clinical trials to conduct various analyses, thereby enhancing the resolution of clinical trial results. Last year, our in-house-discovered compounds ONO-4578 and ONO-2808 achieved POC. To maximize the value of these drug candidates, we are formulating development and clinical trial plans that enable the fastest possible global approvals in Japan, the United States, and Europe, while fully leveraging Deciphera’s development capabilities in the U.S. and Europe with a goal of ensuring the steady execution of global clinical trials.

We are also striving for the introduction of promising new drug candidates through licensing activities and are working to further strengthen research and development activities.

The main results of research and development activities during the fiscal year ended March 31, 2026 (including those on and after March 31, 2026) are as follows.

[Main Progress of Development Pipelines]

<Oncology>

“Opdivo / Nivolumab”

Hepatocellular carcinoma

- In June 2025, an application of combination therapy with Opdivo and Yervoy was approved in Japan for the treatment of unresectable hepatocellular carcinoma.
- In July 2025, an application of combination therapy with Opdivo and Yervoy was approved in South Korea and Taiwan for the treatment of unresectable or metastatic hepatocellular carcinoma.

MSI-H / dMMR Colorectal cancer

- In August 2025, an application of the combination therapy of Opdivo and Yervoy was approved in Japan for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer.
- In January 2026 in Taiwan, and in February 2026 in South Korea, an application of the combination therapy of Opdivo and Yervoy was approved for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) or mismatch repair-deficient (dMMR)colorectal cancer.

Gastric cancer

- In October 2025, phase III trial was conducted in Japan, South Korea, and Taiwan for first-line treatment of gastric cancer using a combination of Opdivo, Yervoy, and chemotherapy. However, as the primary endpoint of overall survival did not show a statistically significant improvement compared to the chemotherapy group, the development has been discontinued.

Bladder cancer

- In April 2026, phase III trial was conducted in Japan in combination therapy of Opdivo and chemotherapy for adjuvant/ neoadjuvant treatment of bladder cancer. However, as the primary endpoint was not met, the development has been discontinued.

“Braftovi (ONO-7702)” / Encorafenib

- In November 2025 in Japan, and in January 2026 in South Korea, an application of ONO-7702, Braftovi (BRAF inhibitor) in combination with cetuximab and chemotherapy (FOLFOX) was approved for the treatment of unresectable advanced or recurrent BRAF mutation-positive colorectal cancer.

"Velexbru (ONO-4059)" / Tirabrutinib hydrochloride
- In August 2025, phase III of ONO-4059, Velexbru (BTK inhibitor), was initiated in the United States for the treatment of recurrent or refractory primary central nervous system lymphoma.
- In December 2025, an application of approval of ONO-4059, Velexbru (BTK inhibitor), was filed in the United States for the treatment of recurrent or refractory primary central nervous system lymphoma.

"QINLOCK (DCC-2618)" / ripretinib
- In March 2026, an application of approval of DCC-2618 (KIT inhibitor) was filed in Japan for the fourth-line treatment of gastrointestinal stromal tumor (GIST), based on the results of global Phase III clinical trials. In addition, phase I of DCC-2618 was initiated in Japan to evaluate the safety and pharmacokinetics of QINLOCK in Japanese patients with GIST.

"ONO-0530" / sapablursen
- In February 2026, an international phase III clinical trial of ONO-0530 (TMPRSS6 gene expression inhibitor) was initiated for the treatment of polycythemia vera.

"DCC-2812"
- In August 2025, phase I of DCC-2812 (GCN2 activator) was initiated in the USA for the potential treatment of renal cell carcinoma, urothelial carcinoma, and castration-resistant prostate cancer.

"ONO-7429"
- In March 2026, phase I of ONO-7429 (anti-L1CAM ADC) was initiated in Japan for the treatment of solid tumor.

"ONO-7018"
- In April 2025, phase I of ONO-7018 (MALT1 inhibitor) was conducted for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia, but the project was discontinued due to strategic reasons.

"ONO-7475 / tamnorzatinib"
- In July 2025, phase I of ONO-7475 (Axl/Mer inhibitor) for the treatment of EGFR-mutated non-small cell lung cancer was conducted in Japan, but the project was discontinued due to strategic reasons.

"DCC-3116 / inlexisertib"
- In September 2025, Phase I/II of DCC-3116 (ULK inhibitor) for the potential treatment of solid tumor (in combination with sotorasib) was conducted in the USA, but this cohort was discontinued due to strategic reasons.

"DCC-3084"
- In September 2025, Phase I/II of DCC-3084 (Pan-RAF inhibitor) for the potential treatment of advanced malignancies was conducted in the USA, but the project was discontinued due to strategic reasons.

"ONO-4578"
- In March 2026, Phase I of ONO-4578 (a prostaglandin EP4 receptor antagonist) for the treatment of hormone receptor-positive, HER2-negative breast cancer was conducted, but the project was discontinued due to strategic reasons.

"ONO-7913 / magrolimab"
- In April 2026, phase I trial of ONO-7913 (anti-CD47 antibody) was conducted in combination therapy with Opdivo for the treatment of pancreatic cancer and colorectal cancer. However, the development has been discontinued due to strategic reasons.

<Areas Other than Oncology>

"ONO-8531 / povetacicept"
- In June 2025, the Company entered into a licensing agreement with Vertex Pharmaceuticals Incorporated for ONO-8531 (povetacicept), which is currently undergoing a Phase III clinical trial for the treatment of IgA nephropathy. Through this agreement, we obtained the rights for development and commercialization in Japan and South Korea.
- Phase IIb/III of ONO-8531 (BAFF/APRIL dual antagonist) for the treatment of membranous nephropathy has been added to the development pipeline.

"Gel-One (ONO-5532)"
- In August 2025, the Company entered into a joint development and commercialization agreement with Seikagaku Corporation on Gel-One (ONO-5532) for the treatment of osteoarthritis. In Japan, a Phase III clinical trial is being conducted for the treatment of knee osteoarthritis and hip osteoarthritis.

"ROMVIMZA (DCC-3014) / vimseltinib"
- In September 2025, an application of DCC-3014, ROMVIMZA (CSF-1R inhibitor), was approved in Europe for the treatment of tenosynovial giant cell tumor associated with clinically significant functional impairment, where surgical treatment is not expected to be effective or may result in intolerable morbidity or disability.

"ONO-2017 / cenobamate"
- In September 2025, an application of ONO-2017 (inhibition of voltage-gated sodium currents/positive allosteric modulator of GABAA ion channel) was filed in Japan for the treatment of partial-onset seizures (including secondary generalized seizures).
- In February 2026, Phase III of ONO-2017 (inhibition of voltage-gated sodium currents/positive allosteric modulator of GABAA ion channel) was initiated for the treatment of partial-onset seizures (pediatric).

"ONO-2416"
- In February 2026, Phase I of ONO-2416 was initiated in healthy volunteers in Japan for the treatment of psychiatric disorders.

"ONO-3310"
- In March 2026, Phase I of ONO-3310 was initiated in Japan for the treatment of kidney diseases.

"ONO-6414"
- In April 2026, Phase I of ONO-6414 was initiated in the USA for the treatment of autoimmune diseases.

[Status of Drug Discovery / Research Alliance Activities]

- In March 2026, the Company entered into an agreement to expand the drug discovery collaboration agreement with Congruence Therapeutics in Canada for the discovery of novel small molecule modulators against multiple protein targets in the areas of neurology and immunology.

[Status of Licensing Activities]

- In June 2025, the Company entered into an exclusive collaboration and licensing agreement for the development and commercialization with Vertex Pharmaceuticals Incorporated in the United States for povetacicept, a therapeutic candidate targeting immunoglobulin A nephropathy (IgAN), primary membranous nephropathy (pMN) and other serious B cell-mediated diseases, in Japan and South Korea.
- In August 2025, the Company entered into an exclusive licensing agreement with Seikagaku Corporation for the co-development and commercialization of Gel-One, a treatment for osteoarthritis, in Japan.

(2) Overview of Financial Position for the Fiscal Year 2025

(Millions of yen)

	As of March 31, 2025	**As of March 31, 2026**	Change
Total assets	1,064,046	**1,106,515**	42,469
Equity attributable to owners of the Company	782,451	**850,727**	68,276
Ratio of equity attributable to owners of the Company to total assets	73.5%	**76.9%**	
Equity attributable to owners of the Company per share	1,665.61 yen	**1,810.44 yen**	

Total assets was ¥1,106.5 billion, increased by ¥42.5 billion from the end of the previous fiscal year.
Current assets increased by ¥13.2 billion to ¥468.3 billion mainly due to an increase in "cash and cash equivalents", despite a decrease in inventories.
Non-current assets increased by ¥29.3 billion to ¥638.2 billion mainly due to increases in intangible assets.
Liabilities decreased by ¥26.0 billion to ¥249.9 billion mainly due to decreases in loans and "trade and other payables", despite an increase in income tax payables.
Equity attributable to owners of the Company increased by ¥68.3 billion to ¥850.7 billion mainly due to the recording of the profit for the year and an increase in other components of equity, despite cash dividends.

(3) Overview of Cash Flows for the Fiscal Year 2025

(Millions of yen)

	Fiscal year ended March 31, 2025	**Fiscal year ended March 31, 2026**	Change
Cash and cash equivalents at the beginning of the period	166,141	**204,567**	
Cash flows from operating activities	82,459	**136,821**	54,361
Cash flows from investing activities	(136,785)	**(39,860)**	96,925
Cash flows from financing activities	94,299	**(65,493)**	(159,792)
Net increase (decrease) in cash and cash equivalents	39,974	**31,468**	
Effects of exchange rate changes on cash and cash equivalents	(1,548)	**1,012**	
Cash and cash equivalents at the end of the fiscal year	204,567	**237,046**	

Net increase/decrease in cash and cash equivalents was an increase of ¥31.5 billion.
Net cash provided by operating activities was ¥136.8 billion, as a result of profit before tax of ¥92.7 billion and "depreciation and amortization" of ¥37.8 billion, etc.
Net cash used in investing activities was ¥39.9 billion, as a result of the acquisition of intangible assets of ¥47.2 billion, etc.
Net cash used in financing activities was ¥65.5 billion, as a result of dividends paid of ¥37.5 billion, and repayments of long-term loans of ¥30.0 billion, etc.

(4) Future Outlook

<Core basis> (Millions of yen)

	Result (Fiscal year ended March 31, 2026)	**Forecast (Fiscal year ending March 31, 2027)**	Change	Change (%)
Revenue	515,785	**455,000**	(60,785)	(11.8) %
Core operating profit	137,135	**124,000**	(13,135)	(9.6) %
Core Profit for the year (attributable to owners of the Company)	103,499	**93,000**	(10,499)	(10.1) %

Note: The annual exchange rate assumed in this forecast is 1 USD = 155 yen.

[Revenue]
Revenue of goods and products are expected to be ¥270.0 billion, a decrease of ¥72.6 billion (21.2%) year on year, mainly due to the absence of sales of Forxiga Tablets following the termination of the co-promotion agreement with AstraZeneca, despite continued growth in prescriptions of Opdivo Intravenous Infusion, QINLOCK, a treatment for gastrointestinal stromal tumors, and ROMVIMZA, a treatment for tenosynovial giant cell tumor (TGCT).
Royalty and others are expected to increase by ¥11.8 billion (6.8%) year on year to ¥185.0 billion, mainly due to increased royalty income from Bristol Myers Squibb and other partners.
Revenue is therefore expected to be ¥455.0 billion, a decrease of ¥60.8 billion (11.8%) year on year.

[Core Operating Profit / Core Profit for the Year]
Cost of sales is expected to be ¥84.0 billion, a decrease of ¥23.0 billion (21.5%) year on year, mainly due to a decrease in sales following the termination of the co-promotion agreement for Forxiga Tablets.

Research and development costs are expected to be ¥143.0 billion, a decrease of ¥2.1 billion (1.5%) year on year. The Company will continue proactive R&D investments, exceeding 30% of net sales, including the conduct of global clinical trials for compounds such as Sapablursen and ONO-4578.

Selling, general, and administrative expenses (except for research and development costs) are expected to be ¥101.0 billion, a decrease of ¥22.6 billion (18.3%) year on year, mainly due to a reduction in co-promotion expenses associated with the termination of the co-promotion agreement for Forxiga Tablets.

Therefore, core operating profit is expected to be ¥124.0 billion, a decrease of ¥13.1 billion (9.6%) year on year, and core profit attributable to owners of the Company is expected to be ¥93.0 billion, a decrease of ¥10.5 billion (10.1%) year on year.

<IFRS full basis> (Millions of yen)

	Result (Fiscal year ended March 31, 2026)	**Forecast (Fiscal year ending March 31, 2027)**	Change	Change (%)
Revenue	515,785	**455,000**	(60,785)	(11.8)%
Operating profit	92,236	**94,000**	1,764	1.9%
Profit before tax	92,654	**94,000**	1,346	1.5%
Profit for the year (attributable to owners of the Company)	69,767	**71,000**	1,233	1.8%

Note: The annual exchange rate assumed in this forecast is 1 USD = 155 yen.

[Revenue]
Revenue (IFRS (full) basis) is the same as on a core basis.

[Operating Profit / Profit for the year]
Operating profit is expected to be ¥94.0 billion, an increase of ¥1.8 billion (1.9%) year on year. This increase is mainly due to the absence in the next fiscal year of one-time expenses recorded in the current fiscal year and excluded from core basis.
Profit attributable to owners of the Company is expected to be ¥71.0 billion, an increase of ¥1.2 billion (1.8%) year on year.

(5) Basic policy for profit distribution and dividends for the fiscal year under review and the following fiscal year

Distribution of profits to all our shareholders is one of our key management policies. We have adopted a progressive policy of maintaining or increasing the annual dividend each year, aiming for a payout ratio of 40%, while considering the performance and various indicators of each fiscal year.
As for the dividend for the fiscal year ended March 31, 2026, we expect to make a year-end dividend of 40 yen per share. With the payment of the second quarter dividend of 40 yen per share, the annual dividend is expected to be 80 yen per share.
Also, the annual dividend for the following fiscal year ending March 31, 2027, is expected to be 80 yen per share.
We actively utilize retained earnings for the future business development including research and development of new innovative drugs in Japan and abroad, alliance with bio-venture companies, and introduction of new drug candidate compounds for development risk reduction.

2. Basic Approach to the Selection of Accounting Standards

Our group has applied International Financial Reporting Standards (IFRS) from the fiscal year ended March 31, 2014, for the purpose of improving comparability by disclosing financial information based on international standards and enhancing the convenience of various stakeholders such as shareholders, investors, and business partners.

3. Consolidated Financial Statements and Major Notes

(1) Consolidated Statement of Financial Position

(Millions of yen)

	As of March 31, 2025	As of March 31, 2026
Assets		
Current assets		
Cash and cash equivalents	204,567	237,046
Trade and other receivables	135,022	145,936
Marketable securities	4,479	60
Other financial assets	1,334	1,565
Inventories	74,864	57,451
Other current assets	34,838	26,249
Total current assets	455,104	468,308
Non-current assets		
Property, plant, and equipment	105,721	101,419
Goodwill	21,186	22,654
Intangible assets	330,041	353,581
Investment securities	88,558	93,193
Other financial assets	7,944	8,109
Deferred tax assets	51,020	55,759
Other non-current assets	4,473	3,492
Total non-current assets	608,942	638,206
Total assets	1,064,046	1,106,515

(Millions of yen)

	As of March 31, 2025	As of March 31, 2026
Liabilities and Equity		
Current liabilities		
Trade and other payables	89,329	62,951
Short-term loans	30,000	35,389
Lease liabilities	3,178	3,078
Other financial liabilities	1,482	1,472
Income taxes payable	4,058	30,778
Other current liabilities	20,249	29,976
Total current liabilities	148,296	163,645
Non-current liabilities		
Long-term loans	105,000	75,000
Lease liabilities	8,500	7,468
Other financial liabilities	0	0
Retirement benefit liabilities	2,640	2,234
Deferred tax liabilities	10,817	909
Other non-current liabilities	590	616
Total non-current liabilities	127,548	86,227
Total liabilities	275,844	249,871
Equity		
Share capital	17,358	17,358
Capital reserves	17,458	17,378
Treasury shares	(63,063)	(62,770)
Other components of equity	19,789	48,674
Retained earnings	790,908	830,086
Equity attributable to owners of the Company	782,451	850,727
Non-controlling interests	5,751	5,917
Total equity	788,203	856,643
Total liabilities and equity	1,064,046	1,106,515

(2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income

Consolidated Statement of Income

(Millions of yen)

	FY2024 (April 1, 2024, to March 31, 2025)	FY2025 (April 1, 2025, to March 31, 2026)
Revenue	486,871	515,785
Cost of sales	(147,950)	(141,716)
Gross profit	338,921	374,069
Selling, general, and administrative expenses	(125,671)	(123,691)
Research and development costs	(149,866)	(147,043)
Other income	1,110	913
Other expenses	(4,746)	(12,012)
Operating profit	59,747	92,236
Finance income	4,774	3,956
Finance costs	(5,318)	(3,539)
Share of profit (loss) from investments in associates	125	—
Profit before tax	59,328	92,654
Income tax expense	(9,163)	(22,743)
Profit for the year	50,166	69,911
Profit for the year attributable to		
Owners of the Company	50,047	69,767
Non-controlling interests	119	144
Profit for the year	50,166	69,911
Earnings per share		
Basic earnings per share (Yen)	106.55	148.49
Diluted earnings per share (Yen)	106.41	148.41

Consolidated Statement of Comprehensive Income

(Millions of yen)

	FY2024 (April 1, 2024, to March 31, 2025)	FY2025 (April 1, 2025, to March 31, 2026)
Profit for the year	50,166	69,911
Other comprehensive income:		
Items that will not be reclassified to profit or loss:		
Net gain (loss) on financial assets measured at fair value through other comprehensive income	(6,517)	11,382
Remeasurements of defined benefit plans	259	1,476
Share of net gain (loss) on financial assets measured at fair value through other comprehensive income of investments in associates	(1)	—
Total of items that will not be reclassified to profit or loss	(6,259)	12,858
Items that may be reclassified subsequently to profit or loss:		
Net gain (loss) on financial assets measured at fair value through other comprehensive income	61	(3)
Exchange differences on translation of foreign operations	(17,128)	22,884
Net fair value gain (loss) on cash flow hedge	2,066	(1,956)
Total of items that may be reclassified subsequently to profit or loss	(15,001)	20,926
Total other comprehensive income	(21,260)	33,784
Total comprehensive income for the year	28,905	103,695
Comprehensive income for the year attributable to:		
Owners of the Company	28,786	103,524
Non-controlling interests	119	172
Total comprehensive income for the year	28,905	103,695

(3) Consolidated Statement of Changes in Equity

FY 2024 (April 1, 2024 to March 31, 2025)

(Millions of yen)

	Equity attributable to owners of the Company							
	Share capital	Capital reserves	Treasury shares	Other components of equity	Retained earnings	Total equity attributable to owners of the Company	Non-controlling interests	Total equity
Balance as of April 1, 2024	17,358	17,458	(63,233)	53,194	768,183	792,961	5,644	798,604
Profit for the year					50,047	50,047	119	50,166
Other comprehensive income				(21,261)		(21,261)	0	(21,260)
Total comprehensive income for the year	–	–	–	(21,261)	50,047	28,786	119	28,905
Purchase of treasury shares			(1)			(1)		(1)
Disposition of treasury shares		(53)	138			85		85
Cash dividends					(37,574)	(37,574)	(11)	(37,585)
Share-based payments		47				47		47
Change in scope of equity method			34			34		34
Transfer from retained earnings to capital reserves		6			(6)	—		—
Transfer from other components of equity to retained earnings				(10,258)	10,258	—		—
Transfer to non-financial assets				(1,886)		(1,886)		(1,886)
Total transactions with the owners	–	–	171	(12,145)	(27,322)	(39,296)	(11)	(39,307)
Balance as of March 31, 2025	17,358	17,458	(63,063)	19,789	790,908	782,451	5,751	788,203

FY 2025 (April 1, 2025 to March 31, 2026)

(Millions of yen)

	Equity attributable to owners of the Company							
	Share capital	Capital reserves	Treasury shares	Other components of equity	Retained earnings	Total equity attributable to owners of the Company	Non-controlling interests	Total equity
Balance as of April 1, 2025	17,358	17,458	(63,063)	19,789	790,908	782,451	5,751	788,203
Profit for the year					69,767	69,767	144	69,911
Other comprehensive income				33,756		33,756	28	33,784
Total comprehensive income for the year	—	—	—	33,756	69,767	103,524	172	103,695
Purchase of treasury shares			(1)			(1)		(1)
Disposition of treasury shares		(127)	294			167		167
Cash dividends					(37,587)	(37,587)	(6)	(37,594)
Share-based payments		47				47		47
Transfer from other components of equity to retained earnings				(6,998)	6,998	—		—
Transfer to non-financial assets				2,127		2,127		2,127
Total transactions with the owners	—	(81)	293	(4,871)	(30,589)	(35,248)	(6)	(35,254)
Balance as of March 31, 2026	17,358	17,378	(62,770)	48,674	830,086	850,727	5,917	856,643

(4) Consolidated Statement of Cash Flows

(Millions of yen)

	FY2024 (April 1, 2024, to March 31, 2025)	FY2025 (April 1, 2025, to March 31, 2026)
Cash flows from operating activities		
Profit before tax	59,328	92,654
Depreciation and amortization	26,894	37,752
Impairment losses	7,981	2,200
Interest and dividend income	(4,632)	(3,457)
Interest expense	1,408	2,158
(Increase) decrease in inventories	12,435	18,962
(Increase) decrease in trade and other receivables	7,391	1,579
Increase (decrease) in trade and other payables	20,909	(26,306)
Increase (decrease) in retirement benefit liabilities	(275)	1,748
Increase (decrease) in accrued consumption tax	(2,123)	4,844
Other	(4,870)	20,693
Subtotal	124,446	152,826
Interest received	1,074	626
Dividends received	2,407	1,940
Interest paid	(1,408)	(2,158)
Income taxes paid	(44,060)	(16,413)
Net cash provided by (used in) operating activities	82,459	136,821
Cash flows from investing activities		
Purchases of property, plant, and equipment	(5,431)	(6,024)
Proceeds from sales of property, plant, and equipment	9	21
Purchases of intangible assets	(2,559)	(47,246)
Purchases of investments	(2,858)	(2,876)
Proceeds from sales and redemption of investments	37,360	17,445
Payments into time deposits	(1,217)	(1,566)
Proceeds from withdrawal of time deposits	203,479	1,230
Payments of the acquisition of subsidiaries	(364,816)	—
Other	(752)	(845)
Net cash provided by (used in) investing activities	(136,785)	(39,860)
Cash flows from financing activities		
Dividends paid	(37,516)	(37,532)
Dividends paid to non-controlling interests	(11)	(6)
Net increase/decrease in short-term loans	—	5,389
Repayment of long-term loans	(15,000)	(30,000)
Proceeds from long-term loans	150,000	—
Repayments of lease liabilities	(3,173)	(3,343)
Purchases of treasury shares	(1)	(1)
Net cash provided by (used in) financing activities	94,299	(65,493)
Net increase (decrease) in cash and cash equivalents	39,974	31,468
Cash and cash equivalents at the beginning of the year	166,141	204,567
Effects of exchange rate changes on cash and cash equivalents	(1,548)	1,012
Cash and cash equivalents at the end of the year	204,567	237,046

(5) Notes to Consolidated Financial Statements

(Note Regarding Assumption of Going Concern)

Not Applicable

(Material Accounting Policies)

The material accounting policies that the Group has applied in the consolidated financial statements are the same as the ones for the previous fiscal year.

(Segment Information)

1) Reportable Segments

Based on the Group's corporate philosophy, "Dedicated to the Fight against Disease and Pain," in order to fulfill medical needs that have not yet been met, the Group is dedicated to developing innovative new pharmaceutical drugs for patients and focuses its operating resources on a single segment of the pharmaceutical business (research and development, purchasing, manufacturing, and sales). Accordingly, segment information is omitted herein.

2) Details of Revenue

Details of revenue are as follows: (Millions of yen)

	FY 2024 (April 1, 2024 to March 31, 2025)	FY 2025 (April 1, 2025 to March 31, 2026)
Revenue of goods and products	330,763	342,607
Royalty and others	156,107	173,178
Total	486,871	515,785

Note: In "Royalty and others", royalty revenue of Opdivo from Bristol-Myers Squibb Company is included, which is ¥113.0 billion for the fiscal year ended March 31, 2025, and ¥122.3 billion for the fiscal year ended March 31, 2026. Royalty revenue of Keytruda® from Merck & Co., Inc. is included, which is ¥26.4 billion for the fiscal year ended March 31, 2025, and ¥29.5 billion for the fiscal year ended March 31, 2026.

3) Revenue by Geographic Area

Details of revenue by geographic area are as follows:

(Millions of yen)

	FY 2024 (April 1, 2024 to March 31, 2025)	FY 2025 (April 1, 2025 to March 31, 2026)
Japan	295,247	287,085
Americas	167,048	197,061
Asia	16,343	17,719
Europe	7,503	12,324
Others	729	1,595
Total	486,871	515,785

Note: Revenue by geographic area is presented on the basis of the place of customers.

4) Major Customers

Details of revenue from major customers are as follows:

(Millions of yen)

	FY 2024 (April 1, 2024 to March 31, 2025)	FY 2025 (April 1, 2025 to March 31, 2026)
Bristol-Myers Squibb Company and the group	124,431	136,704
Medipal Holdings Corporation and the group	71,876	70,458
Suzuken Co., Ltd. and the group	60,674	59,741

(Earnings per Share)

1) Basic Earnings per Share

(i) Basic earnings per share

	FY 2024 (April 1, 2024 to March 31, 2025)	FY 2025 (April 1, 2025 to March 31, 2026)
Basic earnings per share (Yen)	106.55	148.49

(ii) Basis of calculation of basic earnings per share

	FY 2024 (April 1, 2024 to March 31, 2025)	FY 2025 (April 1, 2025 to March 31, 2026)
Profit for the year attributable to owners of the Company (Millions of yen)	50,047	69,767
Weighted-average number of ordinary shares outstanding (Thousands of shares)	469,693	469,852

2) Diluted Earnings per Share

(i) Diluted earnings per share

	FY 2024 (April 1, 2024 to March 31, 2025)	FY 2025 (April 1, 2025 to March 31, 2026)
Diluted earnings per share (Yen)	106.41	148.41

(ii) Basis of calculation of diluted earnings per share

	FY 2024 (April 1, 2024 to March 31, 2025)	FY 2025 (April 1, 2025 to March 31, 2026)
Profit for the year attributable to owners of the Company (Millions of yen)	50,047	69,767
Adjustment to profit for the year attributable to owners of the Company (Millions of yen)	(59)	(16)
Profit for the year used in calculating diluted earnings per share (Millions of yen)	49,988	69,751
Weighted-average number of ordinary shares outstanding (Thousands of shares)	469,693	469,852
Increase in ordinary shares by restricted stock-based remuneration system (Thousands of shares)	75	120
Weighted-average number of diluted ordinary shares outstanding (Thousands of shares)	469,768	469,972

(Significant Subsequent Events)

Not applicable.

Fiscal Year 2025
(April 1, 2025 to March 31, 2026)

Supplementary Materials
(Consolidated IFRS)

ONO PHARMACEUTICAL CO., LTD.

Contents

【Fiscal Year 2025 (April 1, 2025 to March 31, 2026) Consolidated Financial Results (Core basis)】

Page 1	Consolidated Financial Results, Summary of Consolidated Financial Results for FY 2025 (April 1, 2025 to March 31, 2026) (Core Basis)
Page 2	Sales Revenue of Major Products, Details of Sales Revenue, Revenue by Geographic Area
Page 3	Reconciliation from Full to Core basis for FY 2025 (April 1, 2025 to March 31, 2026)
Page 4	Consolidated Financial Forecast, Summary of Consolidated Financial Forecast for FY 2026 (April 1, 2026 to March 31, 2027) (Core Basis)
Page 5	Sales Revenue of Major Products (Forecast), Details of Sales Revenue (Forecast)
Page 6	Depreciation and Amortization, Capital Expenditure and Investments on Intangible Assets Number of Employees
Page 7	Status of Shares
Page 8~12	Main Status of Development Pipelines
Page 13~14	Profile for Main Development

Note: “(Billions of yen)” are rounded.

Consolidated Financial Results for FY 2025 (April 1, 2025, to March 31, 2026) (Core basis)

Consolidated Financial Results (Billions of yen)

	FY 2024 (April 1 2024 to March 31, 2025)	FY 2025 (April 1 2025 to March 31, 2026)	YoY
Revenue	486.9	**515.8**	5.9%
Core operating profit	112.7	**137.1**	21.7%
Core profit for the year (attributable to owners of the Company)	90.4	**103.5**	14.5%

Note: The business of the Company and its affiliates consists of a single segment, the pharmaceutical business.

Summary of Consolidated Financial Results for FY 2025 (April 1, 2025, to March 31, 2026) (Core basis)

1. Revenue ¥515.8 billion YoY an increase of 5.9% (FY 2024 ¥486.9 billion)

<Sales of Domestic Products>

- Sales of domestic products totaled ¥281.4 billion, which was a decrease of ¥10.3 billion (3.5%) year on year.
- Sales of Opdivo Intravenous Infusion for malignant tumors decreased by ¥6.0 billion (5.0%) year on year to ¥114.3 billion, mainly due to the intensified competitive environment. Sales of Forxiga Tablets for diabetes, chronic heart failure and chronic kidney disease decreased by ¥1.4 billion (1.5%) year on year to ¥88.2 billion, mainly due to the entry of generic products in December 2025.
- With respect to other main products, sales of Orencia Subcutaneous Injection for rheumatoid arthritis were ¥26.6 billion (0.0% decrease year on year). Sales of Glactiv Tablets for type-2 diabetes were ¥13.2 billion (27.9% decrease year on year). Sales of Velexbru Tablets for malignant tumors were ¥11.9 billion (12.8% increase year on year). Sales of Ongentys Tablets for Parkinson's disease were ¥9.0 billion (17.3% increase year on year). Sales of Parsabiv Intravenous Injection for Dialysis for secondary hyperparathyroidism on hemodialysis were ¥9.0 billion (6.6% increase year on year). Sales of Kyprolis for Intravenous Infusion for multiple myeloma were ¥7.5 billion (12.9% decrease year on year). Sales of Braftovi Capsules for malignant tumors were ¥5.6 billion (33.8% increase year on year).

<Sales of Overseas Products>

- Sales of overseas products totaled ¥61.2 billion, which was an increase of ¥22.1 billion (56.5%) year on year.
- Sales of QINLOCK® (ripretinib) for gastrointestinal stromal tumor, marketed by Deciphera Pharmaceuticals, LLC, the operating company of Deciphera Pharmaceuticals, Inc., increased by ¥12.9 billion (50.6%) year on year (the previous period included only nine months of sales from July to March) to ¥38.4 billion. Additionally, sales of ROMVIMZA(R) (vimseltinib), also marketed by Deciphera, for tenosynovial giant cell tumor (TGCT) treatment were ¥8.3 billion.

<Royalty and Others>

- Royalty and others increased by ¥17.1 billion (10.9%) year on year to ¥173.2 billion, mainly due to an increase in royalty revenue from Bristol-Myers Squibb Company.

2. Core operating profit ¥ 137.1 billion YoY an increase of 21.7 % (FY 2024 ¥ 112.7 billion)

- Core operating profit was ¥137.1 billion, an increase of ¥24.5 billion (21.7%) year on year.
- Cost of sales was ¥107.0 billion, roughly unchanged from the corresponding period of the previous fiscal year.
- Research and development costs increased by ¥1.8 billion (1.2%) year on year to ¥145.1 billion mainly due to the inclusion of research and development expenses from Deciphera Pharmaceuticals, LLC (the previous period accounted for only nine months of Deciphera's expenses (July to March), whereas the current period includes twelve months (April to March)), despite a decrease in research costs.
- Selling, general, and administrative expenses (except for research and development costs) increased by ¥1.4 billion (1.1%) year on year to ¥123.6 billion mainly due to the inclusion of business operating costs from Deciphera Pharmaceuticals, LLC (the previous period accounted for only nine months of Deciphera's expenses (July to March), whereas the current period includes twelve months (April to March)), despite ongoing efforts to improve cost efficiency.

3. Core profit for the year ¥ 103.5 billion YoY an increase of 14.5 % (FY 2024 ¥ 90.4 billion) (attributable to owners of the Company)

- Core profit attributable to owners of the Company increased by ¥13.1 billion (14.5%) year on year to ¥103.5 billion.

Sales Revenue of Major Products

(Billions of yen)

Product Name	FY 2025 (April 1, 2025 to March 31, 2026) Cumulative					YoY		Forecast
	Apr ~ Jun	Jul ~ Sep	Oct ~ Dec	Jan ~ Mar		Change	Change (%)	
<Domestic>								
Opdivo Intravenous Infusion	29.4	29.1	30.6	25.1	**114.3**	(6.0)	(5.0%)	**120.0**
Forxiga Tablets	25.1	23.7	23.9	15.6	**88.2**	(1.4)	(1.5%)	**80.0**
Orencia for Subcutaneous Injection	7.0	6.8	7.2	5.6	**26.6**	(0)	(0.0%)	**28.0**
Glactiv Tablets	3.6	3.4	3.5	2.8	**13.2**	(5.1)	(27.9%)	**12.0**
Velexbru Tablets	3.0	3.0	3.2	2.7	**11.9**	1.4	12.8%	**11.0**
Ongentys Tablets	2.3	2.2	2.5	2.0	**9.0**	1.3	17.3%	**9.0**
Parsabiv Intravenous Injection	2.2	2.3	2.5	2.1	**9.0**	0.6	6.6%	**9.0**
Kyprolis for Intravenous Infusion	2.0	2.0	2.0	1.5	**7.5**	(1.1)	(12.9%)	**9.0**
Braftovi Capsules	1.3	1.4	1.5	1.5	**5.6**	1.4	33.8%	**–**
<Overseas>								
Opdivo	3.3	3.9	3.6	3.4	**14.2**	1.0	8.0%	**13.5**
QINLOCK	8.9	9.2	10.5	9.7	**38.4**	12.9	50.6%	**36.0**
ROMVIMZA™	1.1	1.7	2.6	2.9	**8.3**	–	–	**8.0**

Notes: 1. Sales revenue of domestic products is shown in a gross sales basis (shipment price).
2. Sales revenue of overseas products is shown in a net sales basis.

Details of Sales Revenue

(Billions of yen)

	FY 2024 (April 1, 2024 to March 31, 2025)	**FY 2025 (April 1, 2025 to March 31, 2026)**
Revenue of goods and products	330.8	**342.6**
Royalty and others	156.1	**173.2**
Total	486.9	**515.8**

Note: In "Royalty and others", royalty revenue of Opdivo from Bristol-Myers Squibb Company is included, which is ¥113.0 billion for the fiscal year ended March 31, 2025, and ¥122.3 billion for the fiscal year ended March 31, 2026. Royalty revenue of Keytruda® from Merck & Co., Inc. is included, which is ¥26.4 billion for the fiscal year ended March 31, 2025, and ¥29.5 billion for the fiscal year ended March 31, 2026.

Revenue by Geographic Area

(Billions of yen)

	FY 2024 (April 1, 2024 to March 31, 2025)	**FY 2025 (April 1, 2025 to March 31, 2026)**
Japan	295.2	**287.1**
Americas	167.0	**197.1**
Asia	16.3	**17.7**
Europe	7.5	**12.3**
Others	0.7	**1.6**
Total	486.9	**515.8**

Note: Revenue by geographic area is presented on the basis of the place of customers.

Reconciliation from Full to Core basis for the FY 2025 (April 1, 2025 to March 31, 2026)

<Definition of core basis>
Core financial results are calculated by deducting items that are not inherently related to the company's business performance or are one-time occurrences from the IFRS-based financial results. Adjustment items include amortization expenses arising from intangible assets acquired through acquisitions or in-licensing, impairment losses, compensation or settlement costs from litigation, and losses due to disasters.

(Billions of Yen)

	IFRS (Full) basis	Amortization	Impairment loss	Others	Core basis
Sales revenue	**515.8**				**515.8**
Cost of sales	**(141.7)**	25.6		9.1	**(107.0)**
Gross profit	**374.1**	25.6		9.1	**408.7**
SG&A expenses	**(123.7)**			0.1	**(123.6)**
R&D costs	**(147.0)**		1.9		**(145.1)**
Other income	**0.9**			(0.2)	**0.7**
Other expenses	**(12.0)**		0.2	8.2	**(3.6)**
Operating profit	**92.2**	25.6	2.1	17.2	**137.1**
Operating profit ratio	**17.9%**				**26.6%**
Finance income	**4.0**			(0.2)	**3.7**
Finance costs	**(3.5)**			0.9	**(2.6)**
Profit before tax	**92.7**	25.6	2.1	17.9	**138.3**
Income tax	**(22.7)**	(6.5)	(0.6)	(4.8)	**(34.6)**
Profit for the year	**69.9**	19.2	1.5	13.1	**103.6**
Non-controlling	**0.1**				**(0.1)**
Profit for the year (Attributable to owners of the company)	**69.8**	19.2	1.5	13.1	**103.5**

Cost of sales – "Other" includes the cost of inventory that was measured at fair value and expensed in connection with the acquisition of Deciphera.
Other expenses – "Other" mainly include the following items:
- A loss of ¥4.3 billion representing the difference between the consideration received for the transfer of selling rights following the termination of the co-promotion agreement with AstraZeneca and the decrease in the carrying amount of the selling rights for Forxiga Tablets.
- A loss of ¥1.7 billion arising from amendments to the retirement benefit plan due to the transition to a defined contribution pension plan.
- A loss of ¥1.4 billion on product recall costs related to certain products.

Consolidated Financial Forecast for FY 2026 (April 1, 2026, to March 31, 2027) (Core Basis)

Consolidated Financial Forecast

(Billions of Yen)

	FY 2024 (April 1, 2024 to March 31, 2025)	FY 2025 (April 1, 2025 to March 31, 2026)	**FY 2026 (April 1, 2026 to March 31, 2027)**	YoY
Revenue	486.9	515.8	**455.0**	(11.8)%
Core operating profit	112.7	137.1	**124.0**	(9.6)%
Core profit for the year (attributable to owners of the Company)	90.4	103.5	**93.0**	(10.1)%

Summary of Consolidated Financial Forecast for FY 2026 (April 1, 2026, to March 31, 2027) (Core basis)

1. Revenue ¥455.0 billion YoY a decrease of ¥60.8 billion (11.8%)

- Revenue of goods and products are expected to be ¥270.0 billion, a decrease of ¥72.6 billion (21.2%) year on year, mainly due to the absence of sales of Forxiga Tablets following the termination of the co-promotion agreement with AstraZeneca, despite continued growth in prescriptions of Opdivo Intravenous Infusion, QINLOCK, a treatment for gastrointestinal stromal tumors, and ROMVIMZA, a treatment for tenosynovial giant cell tumor (TGCT).
- Royalty and others are expected to increase by ¥11.8 billion (6.8%) year on year to ¥185.0 billion, mainly due to increased royalty income from Bristol Myers Squibb and other partners.
- Revenue is therefore expected to be ¥455.0 billion, a decrease of ¥60.8 billion (11.8%) year on year.

2. Core Operating profit ¥124.0 billion YoY a decrease of ¥13.1 billion (9.6%)

- Cost of sales is expected to be ¥84.0 billion, a decrease of ¥23.0 billion (21.5%) year on year, mainly due to the decrease in sales following the termination of the co-promotion agreement for Forxiga Tablets.
- Research and development costs are expected to be ¥143.0 billion, a decrease of ¥2.1 billion (1.5%) year on year. The Company will continue proactive R&D investments, exceeding 30% of net sales, including the conduct of global clinical trials for compounds such as sapablursen and ONO-4578.
- Selling, general, and administrative expenses (except for research and development costs) are expected to be ¥101.0 billion, a decrease of ¥22.6 billion (18.3%) year on year, mainly due to a reduction in co-promotion expenses associated with the termination of the co-promotion agreement for Forxiga Tablets.
- Therefore, core operating profit is expected to be ¥124.0 billion, a decrease of ¥13.1 billion (9.6%) year on year.

3. Core profit for the year ¥93.0 billion YoY a decrease of ¥10.5 billion (10.1%) (attributable to owners of the Company)

- Core profit attributable to owners of the Company is expected to be ¥93.0 billion, a decrease of ¥10.5 billion (10.1%) year on year.

Sales Revenue of Major Products (Forecast)

(Billions of yen)

Product Name	FY 2025 (April 1, 2025 to March 31, 2026) Results	YoY Change	YoY Change (%)	**FY 2026 Forecast (April 1, 2026 to March 31, 2027) Forecast**	YoY Change	YoY Change (%)
<Domestic>						
Opdivo Intravenous Infusion	114.3	(6.0)	(5.0%)	120.0	5.7	5.0%
Orencia for Subcutaneous Injection	26.6	(0.0)	(0.0%)	19.0	(7.6)	(28.6%)
Velexbru Tablets	11.9	1.4	12.8%	12.0	0.1	0.9%
Parsabiv Intravenous Injection	9.0	0.6	6.6%	10.0	1.0	11.2%
Ongentys Tablets	9.0	1.3	17.3%	10.0	1.0	11.5%
Glactiv Tablets	13.2	(5.1)	(27.9%)	9.5	(3.7)	(28.1%)
Braftovi Capsules	5.6	1.4	33.8%	8.5	2.9	51.5%
Kyprolis for Intravenous Infusion	7.5	(1.1)	(12.9%)	7.0	(0.5)	(6.6%)
<Overseas>						
Opdivo	14.2	1.0	8.0%	13.0	(1.2)	(8.2%)
QINLOCK	38.4	12.9	50.6%	43.0	4.6	12.1%
ROMVIMZA	8.3	–	–	19.0	10.7	129.4%

Details of Sales Revenue (Forecast)

(Billions of yen)

	FY 2025 (April 1, 2025 to March 31, 2026)	**FY 2026 Forecast (April 1, 2026 to March 31, 2027)**
Revenue of goods and products	342.6	**270.0**
Royalty and others	173.2	**185.0**
Total	515.8	**455.0**

Depreciation and Amortization, Capital Expenditure and Investments on Intangible Assets

Depreciation and Amortization

(Billions of Yen)

	FY 2024 (April 1, 2024 to March 31, 2025)	**FY 2025 (April 1, 2025 to March 31, 2026)**	**FY 2026 Forecast (April 1, 2026 to March 31, 2027)**
Property, plant, and equipment	10.6	**10.6**	**11.0**
Intangible assets	16.3	**27.2**	**25.1**
Total	26.9	**37.8**	**36.2**
Ratio to sales revenue	5.5%	**7.3%**	**8.0%**

Capital Expenditure (Based on Constructions) and Investments on Intangible Assets

(Billions of yen)

	FY 2024 (April 1, 2024 to March 31, 2025)	**FY 2025 (April 1, 2025 to March 31, 2026)**	**FY 2026 Forecast (April 1, 2026 to March 31, 2027)**
Property, plant, and equipment	8.1	**7.9**	**10.2**
Intangible assets	2.6	**47.1**	**6.3**
Total	10.7	**55.0**	**16.5**

Number of Employees (Consolidated)

	FY 2024 (as of March 31, 2025)	**FY 2025 (as of March 31, 2026)**
Number of employees	4,287	**4,206**

Status of Shares (as of March 31, 2026)

Number of Shares

	As of March 31, 2026
Total number of authorized shares	1,500,000,000
Number of shares issued and outstanding	498,692,800

Number of Shareholders

	As of March 31, 2026
Number of shareholders	111,306

Principal Shareholders

(As of March 31, 2026)

Name of shareholder	Number of shares held (Thousands of shares)	Shareholding percentage
The Master Trust Bank of Japan, Ltd. (Trust account)	65,572	13.70
Custody Bank of Japan, Ltd. (Trust account)	25,228	5.27
Meiji Yasuda Life Insurance Company	18,594	3.88
Ono Scholarship Foundation	16,428	3.43
KAKUMEISOU Co., LTD.	16,158	3.37
JP Morgan Securities Japan Co., Ltd	14,869	3.10
MUFG Bank, Ltd.	8,640	1.80
The Master Trust Bank of Japan, Ltd. (Stock Grant ESOP Trust Account 80358)	8,398	1.75
STATE STREET BANK AND TRUST COMPANY 505001	7,298	1.52
BNYM AS AGT/CLTS 10 PERCENT	6,906	1.44

Notes: 1. The Company is excluded from the principal shareholders listed in the table above, although the Company holds 20,387 thousand shares of treasury share.
2. The shareholding percentage is calculated by deducting treasury share (20,387 thousand shares).

Ownership and Distribution of Shares



Note: The ratio by shareholders listed above is rounded down to two decimal places. Therefore, their total does not amount to 100%.

Main Status of Development Pipelines

As of May 8, 2026, we have listed our pipeline, which includes projects that we are developing clinically either independently (including through our wholly-owned subsidiaries) or in collaboration with partners, as well as those for which we hold contractual rights for potential future clinical development and/or commercialization. Please note that this does not encompass all development activities.

- For regions where we have obtained marketing approval for any indication, the product name is also listed.
- The development stage is indicated for the main countries/regions where we hold rights.
- The start date for clinical trials is based on the date of acceptance of the clinical trial notification, unless otherwise specified.
- Regarding in-house/in-license products, those in which the Ono Group was involved in the drug discovery process during joint research are considered in-house, while those for which we hold commercialization rights are considered in-license. For limited rights, the specific countries/regions are listed separately.

(Oncology)

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
ONO-4538 Nivolumab Opdivo (Intravenous injection)	A human anti-human PD-1 monoclonal antibody	Hepatocellular carcinoma, First-line treatment (Combination with Yervoy)	Approved (Japan) 25/06 Approved (South Korea) 25/07 Approved (Taiwan) 25/07	In-house (Co-development with Bristol-Myers Squibb)
		MSI-H/dMMR colorectal cancer, First-line treatment (Combination with Yervoy)	Approved (Japan) 25/08 Approved (Taiwan) 26/01 Approved (South Korea) 26/02	In-house (Co-development with Bristol-Myers Squibb)
		Hepatocellular carcinoma, Adjuvant therapy	P3	In-house (Co-development with Bristol-Myers Squibb)
		Non-small cell lung cancer, Neoadjuvant and adjuvant therapy (Combination with chemotherapy)	P3	In-house (Co-development with Bristol-Myers Squibb)
		Rhabdoid tumor, Second-line treatment	P2	In-house (Co-development with Bristol-Myers Squibb)
		Richter transformation, Second-line treatment	P2	In-house (Co-development with Bristol-Myers Squibb)
ONO-7702 Encorafenib Braftovi (Oral medication)	BRAF inhibitor	Colorectal cancer, First-line treatment, BRAF-mutation (Combination with Cetuximab and chemotherapy (FOLFOX))	Approved (Japan) 25/11 Approved (South Korea) 26/01	In-license (Japan, South Korea) (Pfizer)
ONO-4059 Tirabrutinib Hydrochloride Velexbru (Oral medication)	BTK (Bruton's tyrosine kinase) inhibitor	Primary central nervous system lymphoma, Second-line treatment and beyond	Filed (USA) 25/12	In-house
		Primary central nervous system lymphoma, second-line treatment and beyond	P3	In-house
		Primary central nervous system lymphoma, First-line treatment	P2	In-house
DCC-2618 ripretinib QINLOCK (Oral medication)	KIT inhibitor	Gastrointestinal stromal tumor, Second-line treatment for patients with KIT exon 11+17/18 mutation	P3	In-house
		Gastrointestinal stromal tumor, Fourth-line treatment	Filed (Japan) 26/03, P1	In-house

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
ONO-0530 sapablursen (Subcutaneous injection)	TMPRSS6 gene expression inhibitor (Oligonucleotide)	Polycythemia vera	P3	In-license (Ionis Pharmaceuticals, Inc)
ONO-4578 (Oral medication)	Prostaglandin receptor (EP4) antagonist	Gastric cancer, First-line treatment (Standard treatment (combination with Opdivo and chemotherapy))	P2	In-house
		Colorectal cancer, First-line treatment (combination with Opdivo and standard treatment)	P2	In-house
		Non-small cell lung cancer, Second-line treatment (combination with Opdivo and standard treatment)	P1	In-house
ONO-4482 relatlimab (Intravenous injection)	Anti-LAG-3 antibody	Melanoma, Second-line treatment and beyond (Combination with Opdivo)	P1/2	In-license (Japan, South Korea, Taiwan) (Co-development with Bristol-Myers Squibb)
ONO-7427 (Intravenous injection)	Anti-CCR8 antibody	Solid tumor (Combination with Opdivo)	P1/2	In-license (Japan, South Korea, Taiwan) (Co-development with Bristol-Myers Squibb)
DCC-3116 inlexisertib (Oral medication)	ULK inhibitor	Advanced malignancies (Combination with ripretinib)	P1/2	In-house
DCC-3009 (Oral medication)	Pan-KIT inhibitor	Gastrointestinal stromal tumor	P1/2	In-house
DCC-2812 (Oral medication)	GCN2 activator	Renal cell carcinoma, urothelial carcinoma, castration-resistant prostate cancer	P1	In-house
ONO-4685 Besufetamig (Intravenous injection)	PD-1 x CD3 bispecific antibody	T-cell lymphoma, Second-line treatment	P1	In-house
ONO-4538HSC (Subcutaneous injection)	A human anti-human PD-1monoclonal antibody	Solid tumor	P1	In-license (Japan, South Korea, Taiwan) (Co-development with Bristol-Myers Squibb)
ONO-8250 (Intravenous injection)	iPS cell-derived HER2-targeted CAR-T cell therapeutics	HER2-expressing solid tumors	P1	In-house (Co-development with Fate Therapeutics, Inc.)
ONO-7428 (Intravenous injection)	Anti-ONCOKINE-1 antibody	Solid tumor	P1	In-license (NEX-I, Inc.)
ONO-7429 (Intravenous injection)	Anti-L1CAM ADC	Solid tumor	P1	In-license (LigaChem Biosciences, Inc.)

(Areas Other than Oncology)

Development code Generic name Product name （Dosage form）	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
DCC-3014 vimseltinib ROMVIMZA (Oral medication)	CSF-1R inhibitor	Tenosynovial giant cell tumor	Approved(USA) 25/02 Approved (Europe) 25/09	In-house
		cGvHD	P2	In-house
ONO-2017 Cenobamate (Oral medication)	Inhibition of voltage-gated sodium currents/positive allosteric modulator of $GABA_A$ ion channel	Partial-onset seizures	Filed (Japan) 25/09	In-license (Japan) (SK Biopharmaceuticals)
		Partial-onset seizures (Pediatric)	P3	In-license (Japan) (SK Biopharmaceuticals)
		Primary generalized tonic-clonic seizures	P3	In-license (Japan) (SK Biopharmaceuticals)
ONO-4059 Tirabrutinib hydrochloride Velexbru （Oral medication）	BTK (Bruton's tyrosine kinase) inhibitor	Steroid-resistant pemphigus	P3	In-house
ONO-8531 povetacicept (Subcutaneous injection)	BAFF/APRIL dual antagonist	Immunoglobulin A nephropathy (IgAN)	P3	In-license (Japan, South Korea) (Vertex Pharmaceuticals Incorporated)
		Membranous nephropathy	P2b/3	In-license (Japan, South Korea) (Vertex Pharmaceuticals Incorporated)
ONO-5532 Gel-One (Intra-articular injection)	Cross-linked hyaluronate	Knee osteoarthritis	P3	In-license (Japan) (Seikagaku Corporation)
		Hip osteoarthritis	P3	In-license (Japan) (Seikagaku Corporation)
ONO-2808 (Oral medication)	S1P5 receptor agonist	Multiple system atrophy	P2	In-house
ONO-2020 (Oral medication)	Epigenetic regulation	Alzheimer's disease	P2	In-house
		Agitation associated with dementia due to Alzheimer's disease	P2	In-house
ONO-1110 (Oral medication)	Endocannabinoid regulation	Postherpetic neuralgia	P2	In-house
		Major depressive disorder	P2	In-house
		Fibromyalgia	P2	In-house
		Social anxiety disorder	P2	In-house
		Hunner type interstitial cystitis	P2	In-house
ONO-4685 Besufetamig (Intravenous injection)	PD-1×CD3 bispecific antibody	Autoimmune disease	P1	In-house
ONO-4915 (Intravenous injection /Subcutaneous injection)	PD-1×CD19 bispecific antibody	Autoimmune disease	P1	In-house

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Phase	In-house / In-license
ONO-2416 (Oral medication)		Psychiatric disorders	P1	In-house
ONO-3310 (Oral medication)		Kidney diseases	P1	In-house
ONO-6414 (Oral medication)		Autoimmune disease	P1	In-house

The change from the announcement of financial results for the Third quarter of the fiscal year ended March 31, 2026, is as follows:

(Oncology)

Development code Generic name Product name (Dosage form)	Pharmacological Action	Target indication (Combination drug)	Development status or reason for termination
ONO-4059 Tirabrutinib Hydrochloride Velexbru (Oral medication)	BTK (Bruton's tyrosine kinase inhibitor)	Primary central nervous system lymphoma, Second-line treatment and beyond	In December 2025, an application of ONO-4059 (BTK inhibitor) was filed in the U.S., for the treatment of recurrent or refractory primary central nervous system lymphoma.
ONO-4538 Nivolumab Opdivo (Intravenous injection)	A human anti-human PD-1 monoclonal antibody	MSI-H/dMMR colorectal cancer, First-line treatment (Combination with Yervoy)	In February 2026, an application of ONO-4538 in combination with Yervoy was approved in South Korea for the treatment of unresectable advanced or recurrent high microsatellite instability (MSI-High) or mismatch repair-deficient (dMMR) colorectal cancer.
ONO-0530 Sapablursen (subcutaneous injection)	TMPRSS6 gene expression inhibitor	Polycythemia vera	In February 2026, an international phase III clinical trial of ONO-0530/sapablursen (TMPRSS6 gene expression inhibitor) was initiated for the treatment of polycythemia vera.
DCC-2618 ripretinib QINLOCK (Oral medication)	KIT inhibitor	Gastrointestinal stromal tumor (GIST) Fourth-line treatment	In March 2026, an application of approval of DCC-2618 (KIT inhibitor) was filed in Japan for the fourth-line treatment of gastrointestinal stromal tumor (GIST), based on the results of global Phase III clinical trials. In addition, phase I of DCC-2618 was initiated in Japan to evaluate the safety and pharmacokinetics of QINLOCK in Japanese patients with GIST.
ONO-4578 (Oral medication)	Prostaglandin EP4 receptor antagonist	Hormone receptor-positive, HER2-negative breast cancer First-line treatment (combination with standard treatment)	In March 2026, Phase I of ONO-4578 (a prostaglandin EP4 receptor antagonist) for the treatment of hormone receptor-positive, HER2-negative breast cancer was conducted, but the project was discontinued due to strategic reasons.
ONO-7429 (Intravenous injection)	Anti-L1CAM ADC	Solid tumor	In March 2026, phase I of ONO-7429 (Anti-L1CAM ADC) was initiated in Japan for the treatment of solid tumor.
ONO-4538 Nivolumab Opdivo (Intravenous Injection)	A human anti-human PD-1 monoclonal antibody	Bladder cancer Adjuvant/neoadjuvant treatment (Combination with chemotherapy)	In April 2026, phase III trial was conducted in Japan in combination therapy of Opdivo and chemotherapy for adjuvant/ neoadjuvant treatment of bladder cancer. However, as the primary endpoint was not met, the development has been discontinued.
ONO-7913 magrolimab (Intravenous Injection)	Anti-CD47 antibody	Pancreatic cancer, First-line treatment (combination with Opdivo) Colorectal cancer First-line treatment (combination with Opdivo)	In April 2026, phase I trial of ONO-7913 (anti-CD47 antibody) was conducted in combination therapy with Opdivo for the treatment of pancreatic cancer and colorectal cancer. However, the development has been discontinued due to strategic reasons.

(Areas Other than Oncology)

Development code Generic name Product name （Dosage form）	Pharmacological Action	Target indication (Combination drug)	Development status or reason for termination
ONO-2017 Cenobamate (Oral medication)	Inhibition of voltage-gated sodium currents/positive allosteric modulator of $GABA_A$ ion channel	Partial-onset seizures (pediatric)	In February 2026, Phase III of ONO-2017 (Inhibition of voltage-gated sodium currents/positive allosteric modulator of $GABA_A$ ion channel) was initiated for the treatment of partial-onset seizures (pediatric).
ONO-8531 povetacicept (Subcutaneous injection)	BAFF/APRIL dual antagonist	Membranous nephropathy	Phase IIb/III of ONO-8531 (BAFF/APRIL dual antagonist) for the treatment of membranous nephropathy has been added to the development pipeline.
ONO-2416 (Oral Medication)		Psychiatric disorders	In February 2026, Phase I of ONO-2416 was initiated in healthy adults in Japan for the treatment of for psychiatric disorders.
ONO-3310 (Oral Medication		Kidney disease	In March 2026, Phase I of ONO-3310 was initiated in Japan for the treatment of kidney diseases.
ONO-6414 (Oral Medication		Autoimmune disease	In April 2026, Phase I of ONO-6414 was initiated in the United States for the treatment of autoimmune diseases.

Profile for Main Development

Opdivo Intravenous Infusion (ONO-4538 / BMS-936558) / Nivolumab (injection)
Opdivo, a human anti-human PD-1 monoclonal antibody, is being developed for the treatment of various kinds of cancers, etc. PD-1 is a receptor expressed on the surface of activated lymphocytes and plays a role in a regulatory pathway that suppresses the activated lymphocytes in the body (negative signal). Research indicates that cancer cells exploit this pathway to escape from immune responses. Opdivo is thought to provide benefit by blocking PD-1-mediated negative regulation of lymphocytes, thereby enhancing the ability of the immune system to recognize cancer cells as foreign and eliminate them.
In Japan, South Korea, and Taiwan, Ono is co-developing this with Bristol-Myers Squibb Company. In the other areas, Bristol-Myers Squibb Company is developing this.

Yervoy Injection (ONO-4480) / Ipilimumab (injection)
Yervoy, a human anti-human CTLA-4 monoclonal antibody, is being developed for the treatment of various kinds of cancer.
In Japan, South Korea, and Taiwan, Ono is co-developing this with Bristol-Myers Squibb Company. In the other areas, Bristol-Myers Squibb Company is developing this.

ONO-4482 / BMS-986016 / relatlimab (injection)
ONO-4482, a human anti-human LAG-3 monoclonal antibody, is being developed for the treatment of melanoma.
In Japan, South Korea, and Taiwan, Ono is co-developing this with Bristol-Myers Squibb Company. In the other areas, Bristol-Myers Squibb Company is developing this.

ONO-4578 (oral)
ONO-4578, a prostaglandin receptor (EP4) antagonist, is being developed for the treatment of gastric cancer, colorectal cancer, and non-small cell lung cancer.

Braftovi Capsules (ONO-7702) / Encorafenib (oral)
Braftovi, a BRAF inhibitor, has been marketed in Japan for the treatment of melanoma, and an additional indication was later approved in Japan for the treatment of BRAF-mutant colorectal cancer. Additionally, we have obtained approval in Japan for the treatment of unresectable BRAF-mutant thyroid cancer and unresectable anaplastic BRAF-mutant thyroid cancer, in combination with Mektovi tablets after progression following cancer chemotherapy. Furthermore, an application was approved in South Korea for the treatment of BRAF-mutant unresectable advanced or recurrent colorectal cancer.

Velexbru Tablets (ONO-4059) / Tirabrutinib Hydrochloride (oral)
Velexbru, a BTK inhibitor, has been marketed in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma, and additional indications were later approved for the treatment of waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma. Additionally, applications were approved in South Korea and Taiwan for the treatment of recurrent or refractory B-cell primary central nervous system lymphoma. Furthermore, an application of approval was filed in the USA for the treatment of primary central nervous system lymphoma. It is also being developed in Japan for the treatment of pemphigus.

ONO-4685 / besufetamig (injection)
ONO-4685, a PD-1 x CD3 bispecific antibody, is being developed for the treatment of autoimmune disease. In the oncology area, it is being developed in Japan and the USA for the treatment of T-cell lymphoma.

ONO-4538HSC (subcutaneous injection)
ONO-4538HSC, a combination drug comprising nivolumab and volhyaluronidase alfa, is being developed in Japan for the treatment of solid tumor.

ONO-8250 (injection)
ONO-8250, an iPS cell-derived HER2-targeted CAR-T cell therapeutics, is being developed in the USA for the treatment of HER2-expressing solid tumor.

ONO-7427 (injection)
ONO-7427, an anti-CCR8 antibody, is being developed in Japan for the treatment of solid tumor.
In Japan, South Korea, and Taiwan, Ono is co-developing this with Bristol-Myers Squibb Company. In the other areas, Bristol-Myers Squibb Company is developing this.

ONO-7428 (injection)
ONO-7428, an anti-ONCOKINE-1 antibody, is being developed in Japan for the treatment of solid tumor.

ONO-0530 / sapablursen (subcutaneous injection)
ONO-0530, an antisense oligonucleotide targeting TMPRSS6, is being developed for the treatment of polycythemia vera.

ONO-2017 / Cenobamate (oral)
An application of ONO-2017, an inhibition of voltage-gated sodium currents / positive allosteric modulator of $GABA_A$ ion channel, for the treatment of partial-onset seizures was filed in Japan. In addition, it is being developed in Japan for the treatment of partial-onset seizures (pediatric) and primary generalized tonic-clonic seizures.

ONO-2808 (oral)
ONO-2808, a S1P5 receptor agonist, is being developed in Japan and the USA for the treatment of multiple system atrophy.

ONO-2020 (oral)
ONO-2020, an epigenetic regulation, is being developed for the treatment of Alzheimer's disease in Japan and the USA, and for the treatment of agitation associated with dementia due to Alzheimer's disease in Japan.

ONO-1110 (oral)

ONO-1110, an endocannabinoid regulation, is being developed in Japan for the treatment of postherpetic neuralgia, major depressive disorder, fibromyalgia, social anxiety disorder, and hunner type interstitial cystitis.

ONO-4915 (injection / subcutaneous injection)

ONO-4915, a PD-1×CD19 bispecific antibody, is being developed in Japan for the treatment of autoimmune disease.

QINLOCK (DCC-2618) / ripretinib (oral)

QINLOCK is a KIT inhibitor that has been approved by the US FDA for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with three or more kinase inhibitors, including imatinib. It is based on the favorable results in fourth-line and fourth-line +GIST patients in the Phase 3 INVICTUS trial and has been approved in regions such as North America, Europe, and Australia. In addition, it is being developed as a potential second-line treatment for GIST patients with KIT exon 11+17/18 mutations. Also, an application of approval was filed in Japan for the fourth-line treatment of GIST.

ROMVIMZA (vimseltinib) (oral)

ROMVIMZA (DCC-3014) is a CSF-1R inhibitor that has been approved in the USA and Europe as a treatment for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. Additionally, it is being developed in the USA as a potential treatment for cGvHD.

DCC-3116 (inlexisertib) (oral)

DCC-3116, a ULK inhibitor, is being developed in combination with ripretinib for the potential treatment of solid tumor in the USA.

DCC-3009 (oral)

DCC-3009, a pan-KIT inhibitor, is being developed in the USA for the potential treatment of gastrointestinal stromal tumor.

ONO-8531 (povetacicept) (subcutaneous injection)

ONO-8531, BAFF/APRIL dual antagonist, is being developed for the treatment of multiple serious B-cell mediated diseases, including IgA nephropathy and primary membranous nephropathy.

ONO-5532 (Gel-One) (intra-articular injection)

ONO-5532 is an intra-articular injection containing cross-linked hyaluronic acid as its active ingredient. It has been marketed overseas since 2012 under the names “Gel-One®” in the United States and “HyLink®” in Taiwan and Italy. In Japan, it is being developed for the treatment of knee osteoarthritis and hip osteoarthritis.

DCC-2812 (oral)

DCC-2812, a GCN2 activation, is being developed for the treatment of renal cell carcinoma, urothelial carcinoma, and castration-resistant prostate cancer.

ONO-7429 (Injection)

ONO-7429, an anti-L1CAM ADC, is being developed for the treatment of solid tumor.

ONO-2416 (oral)

ONO-2416, an in-house drug, is being developed for the treatment of psychiatric disorder.

ONO-3310 (oral)

ONO-3310, an in-house drug, is being developed for the treatment of kidney disease.

ONO-6414 (oral)

ONO-6414, an in-house drug, is being developed for the treatment of autoimmune disease.